ATMA Provides A New View to Mental Healthcare
Psychedelic-Assisted Therapy Training
We are witnessing a new frontier of treatment, providing hope to those struggling with chronic, treatment-resistant mental health concerns.
ATMA’s psychedelic therapy programs and courses establish a standard of care for which mental healthcare practitioners should be trained to effectively work with psychedelics in their practice. Regulatory changes are occurring rapidly; practitioners who achieve competency in this area will be uniquely positioned to adopt psychedelic-assisted therapy treatment into their practices immediately upon legalization of these medicines.
Introduction to Psychedelic-Assisted Therapy (PaT) Course
Introduction to psychedelic-assisted therapy for facilitators, licensed and non-licensed healthcare providers, and anyone who wants to gain familiarity with psychedelics and its therapeutic benefits. This is a prerequisite to the Advanced PaT Certification Program and is a CE credited course.
Advanced Psychedelic-Assisted Therapy (PaT) Certification Program
Comprehensive psychedelic-assisted therapy training for those who wish to integrate PaT into their practice and participate in Health Canada clinical trials. This is a CE credited course.
Physicians & Prescribers Psychedelic-Assisted Therapy (PaT) Course
Designed for licensed medical practitioners, this advanced training course educates and prepares physicians and prescribers to confidently answer questions their patients have about psychedelic-assisted therapy. This is a CME eligible course.
As Featured On
free live webinars
Learn and ask questions about all facets of psychedelic-assisted therapy with our free live webinars
No psychedelic therapy topic is off the table in our monthly live webinars and information sessions.
Clinical Trials and Research on MDMA & Psilocybin Therapy
ATMA is the only training program of its type in the world, as it has a unique link to clinical trials. Upon completing the online learning portion of our Advanced PaT Certification Program, our students will have the opportunity to participate in a psilocybin clinical trial designed for healthcare providers. Later in 2023, we hope to be also approved by Health Canada to conduct MDMA clinical trials similarly.
While the primary objective of our clinical trials is to demonstrate safety and efficacy, our secondary objective is to provide experiential insights into the utility of psychedelic-assisted therapy to healthcare practitioners looking to work in this field.
We take the psychedelic practitioner from training to clinical trials to practice.
ATMA is more than just one of the leading psychedelic-assisted therapy training providers. We also provide the following support for our community:
World class training in multi languages
Regular updating of training program as the field develops
Practice regulation and guidelines support
Access to clinical trials
Community support & psychedelic practitioner directory
Self-Care programs for healthcare practitioners
Third party support services and more
Access to our nationwide network of dosage/facilitation clinics
Integration program for your clients
Our goal is to provide the resources and support that you need to provide psychedelic therapy.
We Are Proud to Support Healthcare Practitioners from Around the World.
We’re proud to support healthcare practitioners from around the world with our programs and initiatives. Learn how our students enjoyed learning with ATMA.
Join the largest community of psychedelic therapy practitioners
Find psychedelic therapy providers, facilitators, and other practitioners in our new directory! If you are a practitioner, increase the visibility of your psychedelic services and expertise by being listed in our directory.
But wait, there’s more!
What’s new in the field of psychedelic-assisted therapy?
Stay up to date on the latest news, research, and regulations for psychedelics.